Magesh Ramasamy

Computational Elucidation of Potent Ligands Targeting Recalcitrant ALK G1202R‐Associated Double Mutations Underlying Lorlatinib Resistance

Targeting ALK has become a viable therapeutic strategy in non‐small cell lung cancer (NSCLC) following the discovery of the EML4‐ALK fusion. Several inhibitors were developed which improved the patient's outcomes; however, the emergence of drug resistance limits the treatment and poses significant challenges. The s...